Hiroki Ishihara
0000-0002-5146-656X
東京女子医科大学附属足立医療センター
65 papers found
Refreshing results…
Association between Ureteral Clamping Time and Acute Kidney Injury during Robot-Assisted Radical Cystectomy
Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinoma
Comparable survival outcome between acquired cystic disease associated renal cell carcinoma and clear cell carcinoma in patients with end-stage renal disease: a multi-institutional central pathology study
Association of tumor burden with outcome in first-line therapy with nivolumab plus ipilimumab for previously untreated metastatic renal cell carcinoma
Prognostic Impact of Trial-Eligibility Criteria in Patients with Metastatic Renal Cell Carcinoma
Tumor response in primary kidney lesions and metastatic lesions in nivolumab plus ipilimumab therapy for advanced renal cell carcinoma without prior nephrectomy: Preliminary results of a multi‐institutional study
Prognostic Impact of Early Treatment Interruption of Nivolumab Plus Ipilimumab Due to Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Multi-Institution Retrospective Study
Outcome of advanced renal cell carcinoma arising in end-stage renal disease: comparison with sporadic renal cell carcinoma
Effect of improved systemic therapy on patient survival in metastatic non‐clear‐cell renal cell carcinoma
Impact of sarcopenia on post-operative outcomes following nephrectomy and tumor thrombectomy for renal cell carcinoma with inferior vena cava thrombus
Assessing improvements in metastatic renal cell carcinoma systemic treatments from the pre-cytokine to the immune checkpoint inhibitor eras: a retrospective analysis of real-world data
Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma
Efficacy of nivolumab versus molecular‐targeted therapy as second‐line therapy for metastatic renal cell carcinoma: Real‐world data from two Japanese institutions
Predictive role of γ-glutamyltransferase in patients receiving nivolumab therapy for metastatic renal cell carcinoma
Prognostic impact of systemic therapy change in metastatic renal cell carcinoma treated with cytoreductive nephrectomy
Genetic and epigenetic profiling indicates the proximal tubule origin of renal cancers in end‐stage renal disease
Prognostic impact of metastasectomy in renal cell carcinoma in the postcytokine therapy era
Nivolumab treatment beyond progression for metastatic renal cell carcinoma: New role of metastasectomy in the immune checkpoint inhibitor era?
Prognostic impact of sarcopenia in patients with metastatic hormone-sensitive prostate cancer
Predictive factors for recurrence after complete metastasectomy in patients with metastatic renal cell carcinoma in the targeted therapy era
Missing publications? Search for publications with a matching author name.